about
Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.Guidelines for antiretroviral therapy for HIV infection. Canadian HIV Trials Network Antiretroviral Working Group.Expanding access to HIV viral load testing: a systematic review of RNA stability in EDTA tubes and PPT beyond current time and temperature thresholdsHost genetics and viral load in primary HIV-1 infection: clear evidence for gene by sex interactionsHuman leukocyte antigens and HIV type 1 viral load in early and chronic infection: predominance of evolving relationshipsDrug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory TrialLow-cost HIV-1 diagnosis and quantification in dried blood spots by real time PCR.Interleukin-27 is differentially associated with HIV viral load and CD4+ T cell counts in therapy-naïve HIV-mono-infected and HIV/HCV-co-infected ChineseDynamics of human immunodeficiency virus type 1 replication in vertically infected infantsStability of human immunodeficiency virus RNA in blood specimens as measured by a commercial PCR-based assayAntiinfectives update: focus on treatment and prevention of viral and associated infections.Intra-assay performance characteristics of five assays for quantification of human immunodeficiency virus type 1 RNA in plasmaQuantification of human immunodeficiency virus type 1 RNA levels in plasma by using small-volume-format branched-DNA assays.Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasmaQuantifying the impact of human immunodeficiency virus-1 escape from cytotoxic T-lymphocytes.Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden.Quantitative molecular virology in patient management.Monitoring patients with HIV diseaseThe role of HIV-proteinase inhibitors.The clinical utility of viral load monitoring in HIV infection: strengths and limitationsModulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients.HIV-1 protease inhibitors.Efficiencies of four versions of the AMPLICOR HIV-1 MONITOR test for quantification of different subtypes of human immunodeficiency virus type 1.One-tube real-time isothermal amplification assay to identify and distinguish human immunodeficiency virus type 1 subtypes A, B, and C and circulating recombinant forms AE and AGQuantitation of human immunodeficiency virus type 1 (HIV-1) RNA in cell-free cervicovaginal secretions: comparison of reverse transcription-PCR amplification (AMPLICOR HIV-A MONITOR 1.5) with enhanced-sensitivity branched-DNA assay (Quantiplex 3.0)Human immunodeficiency virus type 1 drug resistance testing: a comparison of three sequence-based methods.Determinants of hospital admission among HIV-positive people in British Columbia.Quantitation of human immunodeficiency virus type 1 RNA in plasma by using blood dried on filter paper.Absolute copy number and relative change in determinations of human immunodeficiency virus type 1 RNA in plasma: effect of an external standard on kit comparisons.Antiretroviral therapy 2000.The investigation of patients with HIV infection: 10 years of progress.Antiretroviral therapy for human immunodeficiency virus infection in 1997.Determining the number of copies of HIV-1 RNA in plasma: applying this new test to management of patients.Human immunodeficiency virus pathogenesis: insights from studies of lymphoid cells and tissues.Morphological and immunological changes in the skin of autopsied women with AIDS.Comparison of the RealTime HIV-1, COBAS TaqMan 48 v1.0, Easy Q v1.2, and Versant v3.0 assays for determination of HIV-1 viral loads in a cohort of Canadian patients with diverse HIV subtype infections.Role of transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV-1 pathogenesis.Multicenter evaluation of the performance characteristics of the NucliSens HIV-1 QT assay used for quantitation of human immunodeficiency virus type 1 RNAPrognostic significance of HIV-associated oral lesions and their relation to therapy.Metabolic abnormalities in adult HIV infected population on antiretroviral medication in Malaysia: a cross-sectional survey.
P2860
Q24531479-373A90AC-8494-43D2-B020-B2FDD95AFA79Q24534187-29F026C7-3DBA-4F41-93A6-C71FCC16E692Q26860549-51651DEA-F6ED-434E-A5EF-892F3910B398Q28391986-DCBF8095-E952-4E4B-A7C3-DCD4D8133317Q28394085-7BEFDC41-AC50-41E1-91E5-49754A72C3EFQ28552171-B1994A98-C365-4AAE-9F1F-C18F167059D7Q33463338-EE1680D8-3037-44D6-B98E-7E604F445A83Q33590441-B5DAA528-9024-4010-AE30-B3902FC30390Q33639399-0DE17829-8F63-4A17-98D6-1846A649AA86Q33656743-1A5D844E-DD39-4A26-9206-D5DD1D33CE31Q33659379-6DA17FC9-7A20-4EBD-99F4-EF9450D65DCAQ33660617-C1A595D2-6373-4A35-A652-0C5815A953C4Q33674223-90B896F9-E3A4-44CE-841D-B7CF1E43043BQ33678850-7F715910-825F-450D-A64E-05CC3E2B0C2CQ33747537-A978FB07-1041-4634-9CB4-170C70DB59CEQ33883560-9C120E8A-2D66-410C-B6FD-5BF0214D8998Q33893071-D9C9D491-FC87-4E41-BA68-B2EEB2BF0F52Q33925492-0A4564EA-8D4E-45F0-939D-47C7175AF486Q33936186-2CD1A3E0-1217-405E-BFDB-479AEFA05E9EQ33936351-B086F3DF-5C57-4F26-8EF0-F0D85CB246ABQ33945359-CF7446F9-E149-4500-9633-AB446087CCEFQ33946920-3971B753-8BCE-42E1-A36D-08F7884FB5D9Q33958078-F7BDB5B6-9A22-45B4-969B-A8192FCD1A77Q33972312-9941B2FF-2423-4A66-A58B-10317F83140EQ33972457-DF790F00-6004-4B7C-B1DD-B399A8DE7FDCQ33972550-F2277A79-8DA4-4CD5-B1A5-0F1248312EDFQ34034666-3EE4A2FC-351E-450A-86B9-EEC9D61E7014Q34073402-641DDE88-C944-46D0-B64F-C3E4919A5E1EQ34073785-FC54737F-96BD-4407-B861-48D5AFF8C447Q34074272-886A08DD-3661-4959-BA3F-C49B193A1D28Q34140661-2D29AE40-37A5-4EEF-AD5D-04DDD9ED38DDQ34185841-3D8E9ACC-ECA9-4918-965A-1637BE117761Q34186452-8DE9566F-7CF3-448E-97FF-084FA0097E21Q34341001-CD8A3E3D-B6DC-4F1E-95B5-4B77D66D7D90Q34381159-103F7463-BC35-4CC2-90A4-3F75EE6170A3Q34487510-96316FFC-03C1-4CC6-A6AC-0A3647B2A049Q34499377-B910AF06-65E7-495A-86C2-719E4326ABBFQ34747171-FE484289-094F-43C7-983F-FAF9477D33D9Q34775202-6BFBB592-2515-4940-946B-27A6ABE9C410Q34942750-E0430EEF-22DC-4010-B5A0-4C33D26EE74E
P2860
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
HIV viral load markers in clinical practice.
@en
type
label
HIV viral load markers in clinical practice.
@en
prefLabel
HIV viral load markers in clinical practice.
@en
P2093
P2860
P356
P1433
P1476
HIV viral load markers in clinical practice.
@en
P2093
Jacobsen DM
Kuritzkes DR
O'Brien WA
Poscher ME
Richman DD
Volberding PA
P2860
P2888
P304
P356
10.1038/NM0696-625
P407
P577
1996-06-01T00:00:00Z